COO

Business Profile & Competitive Position

The Cooper Companies, Inc. (COO) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. It is a global medical-device company running two segments. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses, including silicone hydrogel lenses, orthokeratology and scleral lenses, plus the myopia-management product MiSight 1 day. CooperSurgical offers more than 600 products and services focused on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services.

The financial signature of its competitive position is mixed. A 5.6% net margin and 2.8% return on equity are both relatively low for a medical-device business; those figures point to limited pricing power across large parts of the portfolio and capital efficiency that has yet to reach premium-device levels. Offsetting that is global scale—products are sold in over 130 countries—and a differentiated regulatory position for MiSight 1 day, which is approved by the FDA, China’s NMPA and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children. So the moat appears to rest more on segmentation, regulatory differentiation and global distribution than on wide, high-margin pricing power.

Financial Posture

Cooper Companies currently carries a $13.6 billion market capitalization and trades at a P/E ratio of 59.0. That multiple is a sizable premium and implies the market is pricing in meaningful long-term growth. Against that, the 5.6% net margin and 2.8% ROE create a valuation-profitability gap: the stock is expensive relative to the returns the business is presently generating. The beta is 0.82, indicating lower systematic volatility than the broader market. At the snapshot, the stock price is $69.59, below the 50-day exponential moving average of $71.82, and the RSI is 37.3, showing near-term momentum has been weak.

Strategic Priorities & Outlook

The company’s most recent 10-K outlines distinct priorities for each segment. CooperVision is focused on driving greater worldwide market penetration of recently introduced products and expanding in both existing and emerging markets. It is also increasing investment in distribution and packaging capabilities to support growth and service levels. A separate educational push aims to develop the myopia-management market by targeting eye-care practitioners, patients and families, with MiSight 1 day as the lead product.

CooperSurgical expects to keep investing in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health. Supporting those agendas are roughly 500 R&D employees split across the two segments and a global footprint covering more than 130 countries, anchored in part by MiSight’s triple regulatory approval in the U.S., China and Japan.

Macro & Geopolitical Exposure

As a Medical - Instruments & Supplies company with worldwide sales, Cooper Companies carries the typical macro exposures of the device industry. Currency risk is material: revenue collected in euros, yen, yuan and other currencies gets translated back into U.S. dollars, so dollar strength can compress reported results. Regulatory exposure spans the FDA, the European Union Medical Device Regulation, China’s NMPA and Japan’s PMDA, any of which could delay launches or change labeling. Trade policy and supply-chain risk matter because contact lenses, devices and packaging move globally, and raw polymers, packaging inputs and freight costs can be affected by tariffs or logistics disruptions. Reimbursement and healthcare spending pressures—public budgets and private payers—can also influence adoption of premium lenses and fertility services.

Recent Developments

The headline flow around the COO ticker heading into September is uneven. The directly relevant item is a Zacks article dated September 3, 2026, “Countdown to The Cooper Companies (COO) Q3 Earnings: Wall Street Forecasts for Key Metrics,” previewing the September 9 report. Two other recent headlines use “COO” to refer to a chief operating officer at unrelated companies: a Motley Fool piece on August 28, 2026, reported that Unity Software COO Alexander Blum sold 22,559 shares for roughly $1 million, and another Fool article on August 23, 2026, discussed Rigetti Computing’s COO selling over 9,000 shares. Those transactions are at different companies and do not carry corporate implications for The Cooper Companies, but they illustrate how ticker-symbol or acronym noise can appear in the same news feed.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, COO beat the consensus EPS estimate in all eight, for a 100% beat rate, with an average earnings surprise of 4.6%. Yet the average five-day price move after those reports is -0.91%, classified as a downward post-earnings drift, showing that beats alone have not reliably produced sustained rallies.

Quarter-by-quarter results reinforce that volatility. On June 4, 2026, the company reported EPS of $1.21 versus a $1.10 estimate, a 10.0% surprise, and the stock rose 8.58% the next day and 8.85% over the following five sessions. The March 5, 2026 quarter delivered EPS of $1.10 against $1.03, a 6.8% beat, but the stock fell 4.55% the next day and 10.82% over five days. On December 4, 2025, EPS of $1.15 beat $1.11 by 3.6%, driving a 5.67% next-day gain and 6.59% over five days. And on August 27, 2025, EPS of $1.10 beat $1.07 by 2.8%, yet the stock dropped 12.86% the next day and 8.24% over the following five sessions.

The next report is scheduled for September 9, 2026 after the market close, with the consensus EPS estimate at $1.12. That sits within the band of recent actuals, and the track record suggests the market may already treat a modest beat as ordinary rather than as a catalyst. The current technical backdrop—price at $69.59, below the 50-day EMA of $71.82 and RSI near 37.3—also shows the stock approaching the release from a soft near-term posture.

For a deeper dive into how institutional analysts weigh these cross-currents, readers can review the full institutional verdict on COO.